Windlas Biotech Limited — Important, 12-11-2024: Financial Result Updates

Windlas Biotech Limited has announced a board meeting. The consolidated financial results for the quarter and half-year ended September 30, 2024, reveal strong revenue growth of 22.5%, reaching ₹1,870.01 crore compared to ₹1,526.72 crore in the same quarter last year. Key drivers include increased demand and operational improvements. Net profit stands at ₹156.58 crore, reflecting a slight decrease from ₹140.31 crore year-over-year, resulting in an earnings per share (EPS) of ₹7.49. Operational costs increased by 17.6% to ₹1,715.56 crore, influenced by higher material consumption and employee expenses. The company’s balance sheet shows total assets of ₹7,468.94 crore, with equity rising to ₹4,712.09 crore. The outlook indicates a focus on sustaining revenue momentum and managing operational costs effectively. Considering overall performance and market conditions, a hold position is suggested for investors.